PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Lupus nephritis

Drugs in development · updated 30 October 2026

Lupus nephritis: drugs in development

As of 30 October 2026 there are 58 active clinical trials (recruiting or ongoing, phases I–III) on 64 drugs for lupus nephritis. 44 are experimental, that is not yet approved in the United States.

58Active trials
44Experimental drugs
2Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
IanalumabVAY736III2NCT05126277
CenerimodIII1NCT07201129
FT819II2NCT07570862
NKX019I–II2NCT06557265
ADX-097II1NCT06419205
AZD0120I–II1NCT06897930
C-CAR168II1NCT07729826
CABA-201I–II1NCT06121297
CART19I–II1NCT06839976
CC-97540II1NCT07015983
CRC01I–II1NCT07364396
DazodalibepVIB4920II1NCT05201469
HLX01II1NCT07038382
HLX79II1NCT07038382
ICG318II1NCT07328581
IL-15II1NCT07328581
PovetaciceptI–II1NCT05732402
SIM0278II1NCT07393451
TelitaciceptII1NCT07340463
TranspoCART19I–II1NCT07799116
AB-101I1NCT06265220
ADI-001I1NCT06375993
ALLO-329I1NCT07085104
BMS-986515I1NCT07115745
BMS-986553I1NCT07873931
CNTY-101I1NCT06255028
CTX112I1NCT06925542
FKC289I1NCT06285279
HB2198I1NCT07491900
KITE-363I1NCT07038447
KYV-101I1NCT06152172
LMY-922I1NCT07729995
NK010I1NCT06676631
NK042I1NCT06676631
OdronextamabOrdspono®I1NCT06975787
SC291I1NCT06294236
STK-009I1NCT06544330
SYNCAR-001I1NCT06544330
UB-VV410I1NCT07109986
VonsetamigI1NCT06975787

Sorted by most advanced phase and number of active trials. Showing 40 of 44 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
ObinutuzumabGazyva®, Gazyvaro®III6NCT04221477
Mycophenolate MofetilMycophenolate, CellceptIII4NCT04702256
AcetaminophenParacetamol, APAPIII3NCT04221477
MethylprednisoloneMethylprednisolon, MethylprenisoloneIII3NCT04221477
PrednisonePredinisone, CortancylIII3NCT04221477
DiphenhydramineBenadryl, Benadryl Preservative Free®III2NCT04221477
AnifrolumabMedi-546, Saphnelo®III1NCT05138133
DexchlorpheniramineIII1NCT04702256
CyclophosphamideCyclophosphamid, CytoxanI–II15NCT06434363
FludarabineFludara, FLUDARABINI–II14NCT06434363
RituximabRuxience, RituxanI–II3NCT05508009
DapagliflozinForxiga, Dapagliflozin PropanediolI–II2NCT07678203
BelimumabBenlysta®II1NCT07340463
DaratumumabDarzalexII1NCT04868838
MelphalanEvomela®, Hepzato®I–II1NCT05508009

Sorted by most advanced phase and number of active trials. Showing 15 of 20 drugs.

All 64 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D008181 “Lupus Nephritis”.

ItalianoFrançaisDeutsch